New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
07:16 EDTGALEGalena Biopharma enrolls first patient in GALE-301 phase 2 trial
Galena Biopharma announced the first patient has been enrolled in the phase 2 trial for GALE-301. GALE-301 is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor as an adjuvant treatment to prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy. The primary objective of the trial is to measure immune response, with secondary outcomes of recurrence. "With GALE-301 progressing into its Phase 2 trial, we continue to demonstrate progress of our innovative cancer immunotherapy pipeline," said Mark Ahn, president and CEO. Initial results from the Phase 1 trial determined the optimal dose and showed that GALE-301 was well tolerated and evoked a FBP specific immunological response.
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
07:25 EDTGALEBiotech Industry Organization to hold a conference
Subscribe for More Information
07:13 EDTGALEGalena receives notice of allowance of U.S. patent for NeuVax
Galena Biopharma announced the United States Patent Office issued a Notice of Allowance for an additional U.S. patent application covering multiple uses of NeuVax. NeuVax is a peptide immunotherapy currently being evaluated for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. This patent will expand both the protection and the potential population of cancer patients NeuVax may address. Once issued, the patent will expire in 2028, not including any patent term extensions.
February 1, 2016
10:08 EDTGALEHigh option volume stocks
High option volume stocks: NOK HLT NCLH DF GALE VMW DPS SYY SYMC PGR

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use